作者: Elizabeth S. Kaufman , Paul A. Zimmermann , Ted Wang , George W. Dennish , Patrick D. Barrell
DOI: 10.1016/J.JACC.2004.06.052
关键词: Risk factor 、 Medicine 、 Cardiology 、 Atrial fibrillation 、 Drug 、 Complication 、 Multivariate analysis 、 Internal medicine 、 Antiarrhythmic agent 、 Anesthesia 、 Ejection fraction 、 Heart disease
摘要: Objectives This study examined the risk of proarrhythmic events in patients receiving antiarrhythmic drugs for treatment atrial fibrillation (AF) according to present-day safety guidelines. Background Advances understanding has led development guidelines these agents. Such were used Atrial Fibrillation Follow-up Investigation Rhythm Management (AFFIRM) study. Methods was an analysis arrhythmic (arrhythmic death, resuscitated cardiac arrest, sustained ventricular tachycardia (VT), and torsade de pointes VT) drug arm AFFIRM Each time begun, it counted as exposure that event calculated. Results A total 2,033 received 3,030 exposures drugs. Ninety-six occurred by six years. Patients with a left ejection fraction Conclusions The overall adverse upon reasonably low. Strict criteria safe use successful minimizing events.